Biotechnology UltraSector ProFund

The Biotechnology UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the Dow Jones U.S. BiotechnologySM Index (the "Index") for a single day.

Fund Snapshot

Investor Class Service Class
Ticker BIPIX BIPSX
CUSIP 743185480 743185472
Fund Number 043 073
Inception Date 6/19/2000
Fund Group Sector ProFunds - UltraSector

Fund Statistics

Limits On Exchanges None
Minimum Investment
Individual Investor $15,000
Financial Professionals $5,000

NAV as of 6/11/2021

Class NAV % Change $ Change
Investor $80.30 -1.47% -$1.20 NAV History
Service $58.34 -1.49% -$0.88 NAV History
BIPIX Current Quote and Chart

Chart data provided by Thomson Reuters.

Returns (as of 3/31/2021)

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost.

For standardized returns year-to-date, and as of the most recent calendar quarter-end, and annualized month-end, see performance. Returns include the reinvestment of dividends and capital gains.

YTD (as of 6/11/2021) 20.26%
Average Annual One Year 46.04%
Average Annual Three Year 12.12%
Average Annual Five Year 12.67%
Average Annual Ten Year 22.41%
Average Annual Since Inception 7.50%
Cumulative Since Inception 349.45%
Gross Expense Ratio 1.61%
Net Expense Ratio * 1.61%

* Contractual waiver effective from December 1, 2020 through November 30, 2021. Without such a waiver of fees, the total returns may have been lower.

All data, unless otherwise noted, is as of 3/31/2021 and for Investor Class Shares only and is subject to change.

Index/Benchmark

Dow Jones U.S. Biotechnology Index

The Index (Bloomberg symbol: DJUSBT) measures the performance of the biotechnology sector of the U.S. equity market. Component companies engage in research and development of biological substances for drug discovery and diagnostic development. These companies derive most of their revenue from the sale or licensing of drugs and diagnostic tools. It is not possible to invest directly in an index.ex.

Total Index Companies 44
Price/Earnings Ratio 26.83
Price/Book Ratio 7.46
Dividend Yield 1.51%
Average Index Market Capitalization 25.41 billion

Index as of 3/31/2021

Index Sector Weightings Weight
Biotechnology 76.49%
Life Sciences Tools & Services 23.16%
Pharmaceuticals 0.34%

Index as of 3/31/2021

Top 10 Index Companies Weight
AbbVie Inc. 17.94%
Amgen Inc. 13.49%
Gilead Sciences Inc. 7.62%
Illumina Inc. 5.26%
Vertex Pharmaceuticals Inc. 5.24%
Regeneron Pharmaceuticals Inc. 4.68%
Biogen Inc. 4.00%
Moderna Inc. 3.73%
Agilent Technologies Inc. 3.64%
IQVIA Holdings Inc. 3.47%